Subclinical Hypothyroidism
Tóm tắt
The term ‘subclinical hypothyroidism’ applies to patients who have mildly increased levels of serum thyrotropin hormone (TSH) and normal levels of thyroxine and liothyronine (triiodiothyronine). This very common condition, also called ‘mild thyroid failure’, accounts for 75% of patients who have increased serum TSH. For patients with sustained increases above 10 mIU/L, there is uniform agreement that thyroxine therapy is indicated. Therapy for milder forms of hypothyroidism is controversial. Some randomized clinical trials favor therapy for mild thyroid failure, but they are inconclusive because they lack stratification for the subgroup of patients with TSH levels below 10 mIU/L. For this subgroup, we recommend individualized management. The presence of goiter, positive thyroperoxidase (TPO) antibodies, manic-depressive disorder, fertility problems, or pregnancy or the anticipation of pregnancy favors the initiation of therapy. Positive TPO antibodies are a strong indication for therapy because of the high likelihood in these patients of progression to overt hypothyroidism; patients who are already receiving thyroxine should have adjustments of their dosage. Children and adolescents with mild thyroid failure should also be treated because of possible adverse effects on growth and development. It has been suggested that subclinical hypothyroidism is a cardiovascular risk factor, however further investigation is needed. The controversy surrounding therapy will not be resolved until more randomized studies are available for the subgroup of patients with TSH <10 mIU/L, and until the question of cardiovascular risk factors is further clarified.
Tài liệu tham khảo
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–99
Fatourechi V. Subclinical thyroid disease. Mayo Clin Proc 2001; 76: 413–6
Cooper DS. Clinical practice: subclinical hypothyroidism. N Engl J Med 2001; 345: 260–5
Klee GG, Hay ID. Biochemical testing of thyroid function. Endocrinol Metab Clin North Am 1997; 26: 763–75
Arem R, Escalante D. Subclinical hypothyroidism: epidemiology, diagnosis, and significance. Adv Intern Med 1996; 41: 213–50
Andersen S, Pedersen KM, Braun NH, et al. Narrow individual variations in serum T4 and T3 in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002; 87: 1068–72
Chu JW, Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 2001; 86: 4591–9
McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 2001; 86: 4585–90
Michalopoulou G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol 1998; 138: 141–5
Bakker SJ, ter Maaten JC, Popp-Snijders C, et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001; 86: 1206–11
Bastenie PA, Bonnyns M, Vanhaelst L. Grades of subclinical hypothyroidism in asymptomatic autoimmune thyroiditis revealed by the thyrotropin-releasing hormone test. J Clin Endocrinol Metab 1980; 51: 163–6
Sheth JJ, Thakore PB, Trivedi BB, et al. Sub-biochemical hypothyroidism: an exaggerated thyroid stimulating hormone response to thyrotropin releasing hormone. J Assoc Physicians India 1999; 47: 275–9
Spencer CA, Schwarzbein D, Guttler RB, et al. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab 1993; 76: 494–8
Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160: 526–34
Yildirimkaya M, Ozata M, Yilmaz K, et al. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43: 731–6
Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132: 270–8
Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996; 6: 155–60
Danese MD, Powe NR, Sawin CT, et al. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996; 276: 285–92
Danese MD, Ladenson PW, Meinert CL, et al. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85: 2993–3001
Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341: 549–55
Klein RZ, Sargent JD, Larsen PR, et al. Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen 2001; 8: 18–20
Glinoer D. Potential repercussions for the progeny of maternal hypothyroxinemia during pregnancy. Thyroid 2000; 10: 59–62
Haggerty Jr JJ, Stern RA, Mason GA, et al. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993; 150: 508–10
Haggerty Jr JJ, Prange Jr AJ. Borderline hypothyroidism and depression. Annu Rev Med 1995; 46: 37–46
Bohnet HG, Fiedler K, Leidenberger FA. Subclinical hypothyroidism and infertility [letter]. Lancet 1981; II: 1278
Tolino A, Nicotra M, Romano L, et al. Subclinical hypothyroidism and hyperprolactinemia. Acta Eur Fertil 1991; 22: 275–7
Strickland DM, Whitted WA, Wians Jr FH. Screening infertile women for subclinical hypothyroidism. Am J Obstet Gynecol 1990; 163: 262–3
Joffe RT, Kutcher S, MacDonald C. Thyroid function and bipolar affective disorder. Psychiatry Res 1988; 25: 117–21
Ananth J, Wohl M, Ranganath V, et al. Rapid cycling patients: conceptual and etiological factors. Neuropsychobiology 1993; 27: 193–8
Terao T. Subclinical hypothyroidism in recurrent mania. Biol Psychiatry 1993; 33: 853–4
Cooper DS, Halpern R, Wood LC, et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med 1984; 101: 18–24
Nystrom E, Caidahl K, Fager G, et al. A double-blind cross-over 12-month study of L-thyroxine treatment of women with ‘subclinical’ hypothyroidism. Clin Endocrinol (Oxf) 1988; 29: 63–75
Jaeschke R, Guyatt G, Gerstein H, et al. Does treatment with L-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism? J Gen Intern Med 1996; 11: 744–9
Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860–6
Kong WM, Sheikh M, Lumb P, et al. A randomised controlled trial of thyroxine treatment in mild subclinical hypothyroidism [abstract]. Endocr Soc Annu Meet Prog Abstr 2000; 82: 597
Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. BMJ 2001; 323: 891–5
Lekakis J, Papamichael C, Alevizaki M, et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values. Thyroid 1997; 7: 411–4
Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55–68
Bunevicius R, Prange AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol 2000; 3: 167–74
Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424–9
Toft AD. Thyroid hormone replacement: one hormone or two? N Engl J Med 1999; 340: 469–70
Halfan M, Redman CC. Clinical guideline, part 2: screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998; 129: 144–58
Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000; 160: 1573–5
Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174–80
Moore DC. Natural course of ‘subclinical’ hypothyroidism in childhood and adolescence. Arch Pediatr Adolesc Med 1996; 150: 293–7
Oppenheimer JH, Braverman LE, Toft A, et al. A therapeutic controversy. Thyroid hormone treatment: when and what? J Clin Endocrinol Metab 1995; 80: 2873–83
Ayala AR, Wartofsky L. The case for more aggressive screening and treatment of mild thyroid failure. Cleve Clin J Med 2002; 69: 313–20
Brent GA. Maternal hypothyroidism: recognition and management. Thyroid 1999; 9: 661–5
Walsh JP, Stuckey BG. What is the optimal treatment for hypothyroidism? Med J Aust 2001; 174: 141–3
Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344: 1743–9
Toft AD. Thyroxine replacement therapy. Ann Acad Med Singapore 1993; 22: 583–6
Fatourechi V, Gharib H. Hyperthyroidism following hypothyroidism: data on six cases. Arch Intern Med 1988; 148: 976–8